Could a Two-Drug combo wipe out breast cancer before surgery?
NCT ID NCT05498155
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests whether giving olaparib (a PARP inhibitor) alone or combined with durvalumab (an immunotherapy) before surgery can eliminate or shrink tumors in people with BRCA-mutated, HER2-negative early breast cancer. Participants receive one of the two treatments for 4–6 months before their planned surgery. The goal is to see if these drugs can destroy cancer cells by exploiting DNA repair weaknesses and boosting the immune system's attack on the tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- olaparib and durvalumab
- What this could lead to
- If successful, this approach could shrink or eliminate tumors before surgery, potentially improving long-term outcomes for people with BRCA-mutated breast cancer.
- What could go wrong
- This is a phase 2 trial with only 50 participants, so results may not apply to everyone. Side effects from the drugs or the combination could occur, and the treatment may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Greeley, Colorado, 80631, United States
-
Research Site
Loveland, Colorado, 80537, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Portland, Oregon, 97239, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Melbourne, 3000, Australia
-
Research Site
Rankweil, 6830, Austria
-
Research Site
Salzburg, 5020, Austria
-
Research Site
Brussels, 1200, Belgium
-
Research Site
Liège, 4000, Belgium
-
Research Site
Augsburg, by, 86156, Germany
-
Research Site
Cologne, 50931, Germany
-
Research Site
Essen, 45130, Germany
-
Research Site
Hamburg, 20246, Germany
-
Research Site
Hanover, 30625, Germany
-
Research Site
Heidelberg, 69120, Germany
-
Research Site
München, 81377, Germany
-
Research Site
Jerusalem, 91120, Israel
-
Research Site
Kfar Saba, 44218, Israel
-
Research Site
Ramat Gan, 5262000, Israel
-
Research Site
Rehovot, 76100, Israel
-
Research Site
Bologna, 40138, Italy
-
Research Site
Meldola, 47014, Italy
-
Research Site
Modena, 41124, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
A Coruña, 15006, Spain
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Barcelona, 8035, Spain
-
Research Site
Cáceres, 10003, Spain
-
Research Site
Hospitalet deLlobregat, 08907, Spain
-
Research Site
Lleida, 25198, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Málaga, 29010, Spain
-
Research Site
Seville, 41009, Spain
-
Research Site
Seville, 41013, Spain
-
Research Site
Valencia, 46010, Spain
-
Research Site
Nottingham, NG5 1PB, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can 3D breast imaging spot more dangerous cancers than standard mammograms?